How Ipamorelin Affects Fasting Glucose

Ipamorelin has a uniquely low insulin resistance profile among GH secretagogues due to the pulsatile nature of its GH stimulation:

1. Pulsatile GH pattern allows insulin sensitivity recovery: Each ipamorelin injection produces a GH pulse that peaks at approximately 40 minutes and resolves within 2-3 hours (Gobburu et al., 1999). During the inter-dose interval, GH levels return to baseline, allowing peripheral tissues to recover insulin sensitivity. This is in contrast to MK-677 (24-hour GH elevation) and exogenous GH at frequent doses, where tissues are continuously exposed to anti-insulin GH signalling.
2. GH-induced insulin resistance mechanism: GH increases insulin resistance by promoting lipolysis and elevating free fatty acid (FFA) availability in peripheral tissues, which competes with glucose uptake in muscle (the Randle cycle). It also directly suppresses insulin receptor signalling in adipose tissue. Pulsatile GH limits FFA elevation to the post-dose window, avoiding the sustained metabolic disruption of continuous GH stimulation.
3. Contrast with MK-677: The Nass et al. (2008, PMID 18981485) 2-year RCT of MK-677 (25 mg/day) documented a 0.3 mmol/L rise in fasting glucose and a 0.2% rise in HbA1c, with 37% of subjects shifting toward pre-diabetic glucose levels. Chapman et al. (1996, PMID 8954023) documented GH's direct insulin-antagonising effects. Ipamorelin avoids sustained GH exposure and therefore avoids these outcomes.
4. No direct pancreatic or ghrelin-receptor-mediated appetite effect: Unlike MK-677, ipamorelin does not activate ghrelin receptors in the pancreas or hypothalamus to stimulate appetite or alter insulin secretion. Its selectivity for GHS-R1a in the pituitary means its metabolic footprint is limited to the transient GH pulse.

Standard dose (200-300 mcg SC, 1-3 times daily):

• Fasting glucose typically unchanged or increased by 0.1-0.2 mmol/L (1-4 mg/dL) at most
• HbA1c: no clinically significant elevation expected at standard doses
• Insulin: no meaningful change; contrast with MK-677 where fasting insulin rises alongside glucose

Stacked with CJC-1295 no-DAC:

• IGF-1 rises more than with ipamorelin alone; the amplified GH pulse may produce a slightly larger glucose transient post-injection, but the inter-dose recovery period remains
• Fasting glucose remains clinically unchanged in most users

Comparison with MK-677 (25 mg/day):

• MK-677 raises fasting glucose 0.3 mmol/L on average (Nass et al., 2008)
• Ipamorelin at standard doses is typically 0.1 mmol/L or less, often undetectable on standard fasting glucose testing

Baseline: Obtain fasting glucose and HbA1c before starting.

During use:

• Fasting glucose quarterly on an ongoing protocol
• HbA1c every 6 months if using long-term
• Increase monitoring frequency if stacking with compounds that independently elevate glucose (AAS, exogenous GH, MK-677) or if baseline fasting glucose is above 5.5 mmol/L (99 mg/dL)

Key advantage: Ipamorelin's metabolic safety profile allows less intensive glucose monitoring than MK-677. Quarterly fasting glucose is sufficient for most users without metabolic risk factors.

Maintaining metabolic safety:

• Inject in a fasted state to maximise GH pulse amplitude and avoid blunting from dietary glucose
• If morning fasting glucose creeps above 5.5 mmol/L (99 mg/dL) on an ongoing ipamorelin protocol, audit for other drivers (AAS use, carbohydrate surplus, reduced activity)
• Metformin is not typically needed for ipamorelin users the way it is sometimes used to offset MK-677's insulin resistance
• Berberine (1500 mg/day) can be used as a conservative measure if any glucose creep occurs

Switching from MK-677 to ipamorelin:

• Users transitioning off MK-677 due to glucose elevation often see fasting glucose normalise within 4-6 weeks
• Switching to ipamorelin (with or without CJC-1295) maintains partial IGF-1 elevation with substantially better metabolic outcomes